for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Illumina, Inc.

ILMN.O

Latest Trade

268.51USD

Change

0.00(0.00%)

Volume

8,886

Today's Range

--

 - 

--

52 Week Range

196.78

 - 

404.20

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
268.51
Open
0.00
Volume
8,886
3M AVG Volume
23.52
Today's High
--
Today's Low
--
52 Week High
404.20
52 Week Low
196.78
Shares Out (MIL)
146.00
Market Cap (MIL)
39,438.98
Forward P/E
65.76
Dividend (Yield %)
--

Next Event

Q3 2020 Illumina Inc Earnings Release

Latest Developments

More

Illumina To Acquire Grail In $8 Billion Cash And Stock Deal

Sequencing Firm Illumina To Pay $7.1 Bln For Liquid-Biopsy Firm Grail - WSJ

Illumina Is In Talks To Acquire Cancer-Detection Startup Grail- Bloomberg Reporter Tweet

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Illumina, Inc.

Illumina, Inc. (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc. (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations. Core Illumina's products and services serve customers in the research, clinical and applied markets, and enable the adoption of a range of genomic solutions. The Company's portfolio of integrated systems, consumables and analysis tools addresses the range of genomic complexity, price points, and throughput, enabling customers to select the solution for their research or clinical challenge. The Company provides reproductive-health solutions, including noninvasive prenatal testing (NIPT), preimplantation genetic screening and diagnosis, and neonatal and genetic health testing.

Industry

Scientific & Technical Instr.

Contact Info

5200 Illumina Way

SAN DIEGO, CA

92122-4616

United States

+1.858.2024500

https://www.illumina.com

Executive Leadership

Jay T. Flatley

Executive Chairman of the Board

Francis A. deSouza

President, Chief Executive Officer, Director

Sam A. Samad

Chief Financial Officer, Senior Vice President

Charles E Dadswell

Senior Vice President, General Counsel, Secretary

Phillip G. Febbo

Senior Vice President, Chief Medical Officer

Key Stats

2.56 mean rating - 18 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

2.8K

2018

3.3K

2019

3.5K

2020(E)

3.1K
EPS (USD)

2017

4.000

2018

5.720

2019

6.570

2020(E)

4.491
Price To Earnings (TTM)
57.82
Price To Sales (TTM)
11.77
Price To Book (MRQ)
8.64
Price To Cash Flow (TTM)
45.07
Total Debt To Equity (MRQ)
25.47
LT Debt To Equity (MRQ)
14.44
Return on Investment (TTM)
11.09
Return on Equity (TTM)
9.75

Latest News

Latest News

Illumina to buy Jeff Bezos-backed cancer testing firm Grail in $8 billion deal

Illumina Inc <ILMN.O> said on Monday it would buy cancer screening startup Grail Inc in a cash-and-stock deal worth $8 billion, buying out investors including Jeff Bezos and snatching back a business it spun out four years ago.

Illumina to pay $7.1 billion for cancer test developer Grail - WSJ

Gene sequencing company Illumina Inc will pay $7.1 billion in cash and stock to buy cancer test startup Grail Inc, the Wall Street Journal reported on Monday, citing people familiar with the matter.

Illumina in talks to buy cancer testing startup Grail: Bloomberg News

Gene sequencing company Illumina Inc <ILMN.O> is in late talks to buy cancer testing startup Grail Inc, Bloomberg News reported on Wednesday, citing people familiar with the matter.

BRIEF-Illumina Says Acquired Bluebee

* ILLUMINA ACQUIRES BLUEBEE TO ACCELERATE PROCESSING, ANALYSIS AND SHARING OF NEXT GENERATION SEQUENCING DATA AT SCALE

BRIEF-Illumina Says U.S. Federal Court Issues Preliminary Injunction Against Bgi Companies

* ILLUMINA INC. ANNOUNCES THAT U.S. FEDERAL COURT ISSUES PRELIMINARY INJUNCTION AGAINST BGI COMPANIES

BRIEF-Yourgene Health Gets CE-IVD Marking For Illumina-Based Iona Test

* YOURGENE HEALTH PLC - RECEIVED CE-IVD MARKING FOR ITS ILLUMINA-BASED IONA® TEST Source text for Eikon: Further company coverage:

BRIEF-Illumina Receives First FDA Emergency Use Authorization For A Sequencing-Based Covid-19 Diagnostic Test

* ILLUMINA RECEIVES FIRST FDA EMERGENCY USE AUTHORIZATION FOR A SEQUENCING-BASED COVID-19 DIAGNOSTIC TEST

BRIEF-Ginkgo Bioworks - Announcing A $70Mm Investment From Illumina

* GINKGO BIOWORKS - ANNOUNCING A $70MM INVESTMENT FROM ILLUMINA

BRIEF-Natera And Illumina Settle Patent Dispute

* ILLUMINA INC - TERMS OF SETTLEMENT BENEFIT BOTH PARTIES, AND SUPPLY AGREEMENT HAS BEEN EXTENDED UNTIL 2030.

Illumina gets patent verdict against Roche upheld on appeal

An appeals court on Friday upheld a $26.7 million patent infringement verdict diagnostics firm Illumina Inc won against rival Roche Holding AG.

BRIEF-Illumina Inc Reports Prelim Revenue For Q1 Of Fiscal Year 2020

* ILLUMINA REPORTS PRELIMINARY REVENUE FOR FIRST QUARTER OF FISCAL YEAR 2020

Illumina gets Section 101 win at Fed Circuit in Roche fetal DNA patent case

A federal appeals court on Tuesday handed a win to genetic testing company Illumina Inc, saying patents it accused Roche Holding AG subsidiary Ariosa Diagnostics of infringing described subject matter eligible for patent protection.

BRIEF-IDbyDNA And Illumina Partner To Deliver NGS Infectious Disease Solutions

* IDBYDNA - CO AND ILLUMINA PARTNER TO DELIVER NGS INFECTIOUS DISEASE SOLUTIONS

BRIEF-Illumina Files Additional Patent Infringement Suit Against BGI In The U.S.

* ILLUMINA FILES ADDITIONAL PATENT INFRINGEMENT SUIT AGAINST BGI IN THE U.S.

BRIEF-Scott Gottlieb Former U.S. FDA Commissioner, Joins Illumina’S Board Of Directors

* DR. SCOTT GOTTLIEB, FORMER US FDA COMMISSIONER, JOINS ILLUMINA’S BOARD OF DIRECTORS

BRIEF-Illumina And Roche Partner To Broaden Patient Access To Genomic Testing

* ILLUMINA AND ROCHE PARTNER TO BROADEN PATIENT ACCESS TO GENOMIC TESTING

Illumina abandons $1.2 billion deal to buy rival Pacific Biosciences

Illumina Inc <ILMN.O> on Thursday agreed to terminate the $1.2 billion deal to buy smaller rival Pacific Biosciences of California Inc <PACB.O>, weeks after the U.S. competition watchdog filed a complaint to block the purchase.

FTC files complaint to block Illumina from buying PacBio

The Federal Trade Commission has filed a complaint aimed at stopping Illumina Inc <ILMN.O> from purchasing Pacific Biosciences of California <PACB.O>, the agency said on Tuesday.

FTC files complaint to block Illumina from buying PacBio

The Federal Trade Commission has filed a complaint aimed at stopping Illumina Inc from purchasing Pacific Biosciences of California, the agency said on Tuesday.

Fed Circuit upholds Illumina victory in Scripps patent fight

Scripps Research, a nonprofit medical research facility in California, on Thursday hit a likely dead end in a lawsuit accusing genomics firm Illumina Inc of infringing a patent related to a type of genetic diagnostic tool.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up